Manuel Morales‐ruiz - Genetic Mutations

Author Information

Manuel Morales-Ruiz is a prominent researcher affiliated with the Biochemistry and Molecular Genetics Department at Hospital Clínic of Barcelona. He is also associated with the Institut d'Investigacions Biomèdiques August Pi i Sunyer and the Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas in Barcelona, Spain. His research focuses primarily on biochemical and metabolic assessments related to liver diseases, including the development and validation of diagnostic methods and therapeutic tools.

Research Contributions

Manuel Morales-Ruiz has made significant contributions to the field of biochemistry and molecular genetics, particularly in the context of liver diseases and metabolic disorders. His recent work includes the development of methods for the quantification of biomarkers associated with diabetes mellitus and liver cirrhosis using advanced techniques such as Gas Chromatography-Mass Spectrometry. Additionally, his research explores novel therapeutic approaches for hepatic fibrosis and liver disease treatment, including the use of cerium oxide nanoparticles and plasmonic hyperthermia.

Aliases

Throughout his academic career, Manuel Morales-Ruiz has been cited under various aliases including M. Morales-Ruiz, M Morales-ruiz, M. A. Morales-ruíz, and several others. These variations often appear in different publications and citation records.

Publication and Citation Metrics

Metric	Value
Total Number of Papers	159
Total Citation Count	7,291
h-index	41

Publications:

Validation of a Microwave-Assisted Derivatization Gas Chromatography-Mass Spectrometry Method for the Quantification of 2-Hydroxybutyrate in Human Serum as an Early Marker of Diabetes Mellitus

DOI: 10.3390/molecules27061889

Year: 2022

Sequential changes in urinary biomarker levels in patients with cirrhosis and severe hepatorenal syndrome

DOI: 10.1111/liv.15069

Year: 2021

Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis.

DOI: 10.1016/j.jhep.2021.08.031

Year: 2021

Validation of a Gas Chromatography-Mass Spectrometry Method for the Measurement of the Redox State Metabolic Ratios Lactate/Pyruvate and β-Hydroxybutyrate/Acetoacetate in Biological Samples

DOI: 10.3390/ijms22094752

Year: 2021

Valoración bioquímica en la enfermedad hepática grasa asociada a la disfunción metabólica

DOI: 10.1515/ALMED-2020-0062

Year: 2021

Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis

DOI: 10.1002/hep4.1881

Year: 2021

Treatment of Hepatic Fibrosis in Mice Based on Targeted Plasmonic Hyperthermia.

DOI: 10.1021/acsnano.1c00988

Year: 2021

Cerium Oxide Nanoparticles: A New Therapeutic Tool in Liver Diseases

DOI: 10.3390/antiox10050660

Year: 2021

Mesoporous silica coated CeO2 nanozymes with combined lipid-lowering and antioxidant activity induce long-term improvement of the metabolic profile in obese Zucker rats.

DOI: 10.1039/D1NR00790D

Year: 2021

Biochemical assessment of metabolic associated fatty liver disease

DOI: 10.1515/almed-2021-0009

Year: 2021

What are the Applications of Populace Genomics?

Why is Prenatal Screening Important?

How Are Nucleotide Mutations Detected?

Are There Potential Treatments Targeting Genetic Mutations?

How Does Genetic Counseling Assist During Pregnancy?

What is Radiation?

What Research is Being Conducted?

How Are Genetic Mutations Mapped in Phylogenetic Trees?

How Do Epigenetics Influence Development?

What Is the Future of PARP Inhibitors?

Partnered Content Networks

Relevant Topics